|
1
|
Humbert M, Montani D, Perros F, Dorfmuller
P, Adnot S and Eddahibi S: Endothelial cell dysfunction and cross
talk between endothelium and smooth muscle cells in pulmonary
arterial hypertension. Vascul Pharmacol. 49:113–118. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Konukoglu D and Uzun H: Endothelial
dysfunction and hypertension. Adv Exp Med Biol. 956:511–540. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cahill PA and Redmond EM: Vascular
endothelium-Gatekeeper of vessel health. Atherosclerosis.
248:97–109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martelli A, Testai L, Anzini M, Cappelli
A, Di Capua A, Biava M, Poce G, Consalvi S, Giordani A, Caselli G,
et al: The novel anti-inflammatory agent VA694, endowed with both
NO-releasing and COX2-selective inhibiting properties, exhibits
NO-mediated positive effects on blood pressure, coronary flow and
endothelium in an experimental model of hypertension and
endothelial dysfunction. Pharmacol Res. 78:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lankhorst S, Kappers MH, van Esch JH,
Danser AH and van den Meiracker AH: Hypertension during vascular
endothelial growth factor inhibition: Focus on nitric oxide,
endothelin-1, and oxidative stress. Antioxid Redox Signal.
20:135–145. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang PW, Yu CL, Wang YZ, Luo SF, Sun LS
and Li RS: Influence of
3,4′,5-trihydroxystibene-3-beta-mono-D-glucoside on vascular
endothelial epoprostenol and platelet aggregation. Zhongguo Yao Li
Xue Bao. 16:265–268. 1995.PubMed/NCBI
|
|
7
|
Gizard F and Bruemmer D: Transcriptional
control of vascular smooth muscle cell proliferation by peroxisome
proliferator-activated receptor-gamma: Therapeutic implications for
cardiovascular diseases. PPAR Res. 2008:4291232008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Carney EF: Hypertension: New non-RAS
peptide modulates the vasoregulatory effects of angiotensin II. Nat
Rev Nephrol. 11:3172015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ceriello A, Novials A, Ortega E, Canivell
S, La Sala L, Pujadas G, Esposito K, Giugliano D and Genovese S:
Glucagon-like peptide 1 reduces endothelial dysfunction,
inflammation, and oxidative stress induced by both hyperglycemia
and hypoglycemia in type 1 diabetes. Diabetes Care. 36:2346–2350.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chaturvedi LS and Basson MD: Glucagonlike
peptide 2 analogue teduglutide: Stimulation of proliferation but
reduction of differentiation in human Caco-2 intestinal epithelial
cells. JAMA Surg. 148:1037–1042. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dang LT, Feric NT, Laschinger C, Chang WY,
Zhang B, Wood GA, Stanford WL and Radisic M: Inhibition of
apoptosis in human induced pluripotent stem cells during expansion
in a defined culture using angiopoietin-1 derived peptide QHREDGS.
Biomaterials. 35:7786–7799. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fosgerau K and Hoffmann T: Peptide
therapeutics: Current status and future directions. Drug Discov
Today. 20:122–128. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaspar AA and Reichert JM: Future
directions for peptide therapeutics development. Drug Discov Today.
18:807–817. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anand IS, Fisher LD, Chiang YT, Latini R,
Masson S, Maggioni AP, Glazer RD, Tognoni G and Cohn JN; Val-HeFT
Investigators, : Changes in brain natriuretic peptide and
norepinephrine over time and mortality and morbidity in the
Valsartan heart failure trial (Val-HeFT). Circulation.
107:1278–1283. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Armstrong PW and Rouleau JL: A canadian
context for the acute study of clinical effectiveness of nesiritide
and decompensated heart failure (ASCEND-HF) trial. Can J Cardiol.
24 (Suppl B):30B–32B. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cerrato BD, Carretero OA, Janic B, Grecco
HE and Gironacci MM: Heteromerization between the bradykinin B2
receptor and the angiotensin-(1–7) mas receptor: Functional
consequences. Hypertension. 68:1039–1048. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koid SS, Ziogas J and Campbell DJ:
Aliskiren reduces myocardial ischemia-reperfusion injury by a
bradykinin B2 receptor- and angiotensin AT2 receptor-mediated
mechanism. Hypertension. 63:768–773. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mughal A and O'Rourke ST: Vascular effects
of apelin: Mechanisms and therapeutic potential. Pharmacol Ther.
190:139–147. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dallas DC, Guerrero A, Parker EA, Robinson
RC, Gan J, German JB, Barile D and Lebrilla CB: Current
peptidomics: Applications, purification, identification,
quantification, and functional analysis. Proteomics. 15:1026–1038.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Slavoff SA, Mitchell AJ, Schwaid AG,
Cabili MN, Ma J, Levin JZ, Karger AD, Budnik BA, Rinn JL and
Saghatelian A: Peptidomic discovery of short open reading
frame-encoded peptides in human cells. Nat Chem Biol. 9:59–64.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rubakhin SS, Churchill JD, Greenough WT
and Sweedler JV: Profiling signaling peptides in single mammalian
cells using mass spectrometry. Anal Chem. 78:7267–7272. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ashburner M, Ball CA, Black JA, Botstein
D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT,
et al: Gene ontology: Tool for the unification of biology: The Gene
ontology Consortium. Nat Genet. 25:25–29. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gene Ontology Consortium: The Gene
Ontology resource: Enriching a GOld mine. Nucleic Acids Res.
49:D325–D334. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanehisa M: Toward pathway engineering: A
new database of genetic and molecular pathways. Sci Technol Japan.
59:34–38. 1996.
|
|
25
|
Liu S, Yi F, Cheng W, Qu X and Wang C:
Molecular mechanisms in vascular injury induced by hypertension:
Expression and role of microRNA-34a. Exp Ther Med. 14:5497–5502.
2017.PubMed/NCBI
|
|
26
|
Reichlin T, Wild A, Durrenberger M,
Daniels AU, Aebi U, Hunziker PR and Stolz M: Investigating native
coronary artery endothelium in situ and in cell culture by scanning
force microscopy. J Struct Biol. 152:52–63. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Biancardi VC, Bomfim GF, Reis WL,
Al-Gassimi S and Nunes KP: The interplay between Angiotensin II,
TLR4 and hypertension. Pharmacol Res. 120:88–96. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cha SA, Park BM and Kim SH:
Angiotensin-(1–9) ameliorates pulmonary arterial hypertension via
angiotensin type II receptor. Korean J Physiol Pharmacol.
22:447–456. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang Y, Tian T, Wang Y, Li Z, Xing K and
Tian G: SIRT6 protects vascular endothelial cells from angiotensin
II-induced apoptosis and oxidative stress by promoting the
activation of Nrf2/ARE signaling. Eur J Pharmacol. 859:1725162019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Song J, Huang S, Wang K, Li W, Pao L, Chen
F and Zhao X: Long Non-coding RNA MEG3 attenuates the angiotensin
II-induced injury of human umbilical vein endothelial cells by
interacting with p53. Front Genet. 10:782019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xu J, Sheng Z, Li F, Wang S, Yuan Y, Wang
M and Yu Z: NEDD4 protects vascular endothelial cells against
Angiotensin II-induced cell death via enhancement of XPO1-mediated
nuclear export. Exp Cell Res. 383:1115052019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li F, Wang Y, Li C, Marquez-Lago TT, Leier
A, Rawlings ND, Haffari G, Revote J, Akutsu T, Chou KC, et al:
Twenty years of bioinformatics research for protease-specific
substrate and cleavage site prediction: A comprehensive revisit and
benchmarking of existing methods. Brief Bioinform. 20:2150–2166.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu P, Mo Y, Peng M, Tang T, Zhong Y, Deng
X, Xiong F, Guo C, Wu X, Li Y, et al: Emerging role of
tumor-related functional peptides encoded by lncRNA and circRNA.
Mol Cancer. 19:222020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Huang JZ, Chen M, Chen D, Gao XC, Zhu S,
Huang H, Hu M, Zhu H and Yan GR: A peptide encoded by a putative
lncRNA HOXB-AS3 suppresses colon cancer growth. Mol Cell.
68:171–184. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Matsumoto A, Pasut A, Matsumoto M,
Yamashita R, Fung J, Monteleone E, Saghatelian A, Nakayama KI,
Clohessy JG and Pandolfi PP: mTORC1 and muscle regeneration are
regulated by the LINC00961-encoded SPAR polypeptide. Nature.
541:228–232. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ellinsworth DC: Arsenic, reactive oxygen,
and endothelial dysfunction. J Pharmacol Exp Ther. 353:458–464.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Q, Zhang M, Ding Y, Wang Q, Zhang W,
Song P and Zou MH: Activation of NAD(P)H oxidase by
tryptophan-derived 3-hydroxykynurenine accelerates endothelial
apoptosis and dysfunction in vivo. Circ Res. 114:480–492. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang L, Tang L, Dai F, Meng G, Yin R, Xu X
and Yao W: Raf-1/CK2 and RhoA/ROCK signaling promote TNF-α-mediated
endothelial apoptosis via regulating vimentin cytoskeleton.
Toxicology. 389:74–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kueper T, Grune T, Prahl S, Lenz H, Welge
V, Biernoth T, Vogt Y, Muhr GM, Gaemlich A, Jung T, et al: Vimentin
is the specific target in skin glycation. Structural prerequisites,
functional consequences, and role in skin aging. J Biol Chem.
282:23427–23436. 2007. View Article : Google Scholar : PubMed/NCBI
|
